Latest News

If you are wondering whether Houlihan Lokey's current share price really lines up with its underlying worth, you are in the right place. This article will walk through what the numbers actually say about value. The stock closed at US$157.30, with returns of a 7% decline over the past week, a 4.3% decline over the past month, a 10.8% decline year to date, but a 1.3% gain over 1 year, 83.3% over 3 years and 153.1% over 5 years. This performance can naturally raise questions about how much...

Why George Weston Is On Investors’ Radar Today George Weston (TSX:WN) has recently drawn attention after a mixed run in its share performance, with the stock showing a 1.5% decline over the past day and a 5.7% decline over the past week. See our latest analysis for George Weston. That short stretch of weaker share price returns, including the recent 7 day and 30 day declines, sits alongside a much stronger picture over time. The 1 year total shareholder return of 19.8% and a 5 year total...

Wondering whether Iridium Communications' share price reflects its true worth, or if the market is missing something that you could be seeing instead? The stock last closed at US$23.95, with recent returns of 6.5% over 7 days, 22.1% over 30 days and 34.9% year to date. The 1‑year return sits at an 18.8% decline, and the 3‑ and 5‑year returns are 57.3% and 39.2% declines respectively. Recent attention on Iridium Communications has been driven less by a single headline and more by ongoing...

If you are wondering whether Plains GP Holdings is still good value after its recent run, this article walks through what the current price might be implying about the business. The stock last closed at US$23.70, with returns of 6.8% over 7 days, 12.3% over 30 days, 22.1% year to date, 26.1% over 1 year, and a very large gain over 5 years. Recent coverage has focused on Plains GP Holdings as an energy infrastructure player that continues to attract attention, with investors watching how it...

If you are wondering whether EPR Properties is offering good value at its current price, this article will walk you through what the numbers are really saying about the stock. The shares last closed at US$57.56, with returns of 4.0% over 30 days, 13.4% year to date, 16.4% over 1 year, 83.3% over 3 years, and 67.3% over 5 years. These figures may influence how investors think about both its potential and its risks. Recent attention on EPR Properties has centered on its positioning as a real...

PagSeguro Digital (NYSE:PAGS) has just wrapped up FY 2025 with Q4 revenue of R$5.2b and basic EPS of R$1.74, alongside net income of R$502.0m. These figures put fresh numbers on the table for investors watching its profitability profile. Over recent periods, the company has seen revenue move from R$5.0b in Q4 2024 to R$5.2b in Q4 2025, while basic EPS shifted from R$1.93 to R$1.74. Trailing twelve month EPS stands at R$7.18 on revenue of R$19.7b and net income of R$2.1b, setting the context...

CStone Pharmaceuticals previously announced that the UK MHRA has granted a new indication for sugemalimab monotherapy in certain adult patients with unresectable stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiotherapy. This adds to approvals by the European Commission and UK MHRA across multiple non-small cell lung cancer settings, potentially broadening sugemalimab’s clinical footprint in key international markets. We will now examine how...

AppFolio recently outlined that revenue growth is outpacing customer additions as users adopt more paid services, supporting higher free-cash-flow margins and a broader mix of income streams, including services sold directly to residents on its platform. Management’s guidance for 2026, including revenue of about US$1.10 billion and a larger adjusted operating margin near 26.5%, highlights how operating leverage and deeper monetization per unit are reshaping the company’s profit...

Bayer FY 2025 earnings snapshot Bayer (XTRA:BAYN) has capped FY 2025 with a tough final quarter, posting Q4 revenue of €11.4 billion and a basic EPS loss of €3.80, alongside a net loss of €3.8 billion. Over recent periods, the company has seen quarterly revenue move between €9.7 billion and €13.7 billion, while EPS has swung from a profit of €1.32 in Q1 2025 to losses in each of the following quarters. This keeps the focus firmly on how quickly margins can stabilize. With forecasts in the...

What Savaria’s latest earnings signal for investors Savaria (TSX:SIS) just reported record 2025 results, including its highest quarterly EBITDA, full year revenue of CA$913.53 million, and net income of CA$68.77 million, closing out its two year Savaria One transformation program. Earnings per share from continuing operations reached CA$0.96 on a basic basis and CA$0.95 on a diluted basis, while both the Accessibility and Patient Care segments contributed to the stronger full year...

If you are wondering whether Atlantic Union Bankshares is offering fair value at its current share price, this article walks through what the numbers are really saying about the stock. The shares most recently closed at US$36.56, with returns of 2.9% year to date and 14.2% over 1 year, while the past 7 days and 30 days have seen declines of 7.5% and 9.8% respectively. Recent moves in regional bank stocks, including Atlantic Union Bankshares, have been shaped by ongoing headlines around...

CSL (ASX:CSL) is back in focus after two fresh developments: a larger on market share buy back now covering nearly four million shares, and a new Canadian pandemic influenza vaccine contract for CSL Seqirus. See our latest analysis for CSL. Despite the fresh buy back and the Canadian vaccine contract, CSL's share price has had a weak patch, with a 30 day share price return of 19.5% and a 1 year total shareholder return decline of 42.6%, pointing to fading momentum after several tougher...

If you are wondering whether Concentrix is a bargain or a value trap at around US$34.50 per share, looking closely at its valuation story is a good place to start. The stock has recently shown a 7.6% gain over the last 7 days, but that comes after weaker returns of a 7.5% decline over 30 days, a 16.3% decline year to date, a 20.4% decline over 1 year, and 72.8% and 73.6% declines over 3 and 5 years respectively. These moves have been happening alongside ongoing attention on Concentrix as a...

Context for Renesas Electronics after recent performance moves Renesas Electronics (TSE:6723) has drawn fresh attention after a mixed stretch of returns, with a small 1 day decline, a weaker past week, and positive performance over the month and past 3 months. For investors following the stock, this pattern, together with a 1 year total return in positive territory and multi year gains, raises questions about how current pricing lines up with its fundamentals and risk profile. See our latest...

In late February 2026, Mesoblast reported half-year results showing revenue of US$51.34 million, a very large increase from US$3.16 million a year earlier, alongside a narrower net loss of US$40.16 million and reduced loss per share. Soon after, the company issued fiscal 2026 guidance projecting full-year Ryoncil net revenue between US$110 million and US$120 million, giving investors a clearer view of the therapy’s commercial trajectory. With Mesoblast now guiding Ryoncil net revenue of...

If you are wondering whether Saia's current share price lines up with its underlying worth, you are not alone. This article is going to focus squarely on what you are paying versus what you might be getting. Saia's stock closed at US$396.62, with a 1.9% decline over the last 7 days, a 6.0% return over 30 days, 17.6% year to date, 3.7% over 1 year, 41.3% over 3 years, and 82.3% over 5 years. This gives you a wide range of time frames to think about risk and reward. Recent news coverage around...

What the latest earnings and M&A plans mean for Everus Construction Group stock Everus Construction Group (ECG) just paired a strong 2025 earnings update with 2026 revenue guidance of US$4.1b to US$4.2b, alongside plans to pursue acquisitions using its current balance sheet capacity. See our latest analysis for Everus Construction Group. The earnings update and new M&A push come after a sharp run in the shares, with a 1 month share price return of 20.5% and a year to date share price return...

In late February 2026, Ambarella, Inc. reported fourth-quarter sales of US$100.87 million and a net loss of US$16.44 million, alongside full-year sales of US$390.70 million and a reduced annual net loss of US$75.87 million compared with the prior year. Management also issued revenue guidance of US$97.00 million to US$103.00 million for the first quarter of fiscal 2027 and projected total revenue growth of 10% to 15% for fiscal 2027, underscoring ongoing demand for its Edge-AI system-on-chip...

Bullish (BLSH) has caught investor attention after a recent swing in performance, with the stock showing a mix of sharp short term gains and declines across the past week and past 3 months. See our latest analysis for Bullish. At a share price of $35.02, Bullish reflects a sharp 26.7% 1 month share price return but a weaker 10.8% year to date share price return, suggesting recent momentum has picked up after earlier weakness. If Bullish’s swings have you thinking about where else growth...

Lumine Group (TSXV:LMN) closed out FY 2025 with Q4 revenue of US$216.3 million and basic EPS of US$0.19, while trailing twelve month figures stood at US$765.7 million in revenue and EPS of US$0.46 as earnings moved into positive territory over the past year. The company reported quarterly revenue rising from US$187.1 million in Q4 2024 to US$216.3 million in Q4 2025, with basic EPS increasing from US$0.11 to US$0.19 over the same period, indicating firmer margins underpinning the latest...

If you are trying to figure out whether Archrock's current share price lines up with its underlying worth, you are in the right place. Archrock's share price recently closed at US$35.80, with returns of 1.0% over 7 days, 20.0% over 30 days, 34.4% year to date and 56.3% over 1 year, while the 3 year and 5 year returns are very large. Recent coverage has focused on Archrock's position in the energy infrastructure space and how investors might be thinking about its long term cash generation and...

If you are wondering whether ArriVent BioPharma's current share price lines up with its underlying worth, you are exactly the audience this valuation focused review is written for. The stock last closed at US$25.25, with reported returns of 8.7% over 7 days, 11.6% over 30 days, 21.4% year to date, and 15.8% over the past year. Recent price moves sit against a backdrop of ArriVent BioPharma working to bring its pipeline to market and building out its position in the pharmaceuticals and...

If you are wondering whether Lindblad Expeditions Holdings at around US$18.21 is still offering value after a strong run, you are not alone. The stock has seen a 10% decline over the last 7 days, after a 4.4% gain over 30 days, and it sits on year to date and 1 year returns of 26.1% and 72.8% respectively, with a 3 year return of 108.8% and a 5 year return of a 9.9% decline. This mix of recent pullback and longer term gains often lines up with changing expectations around growth, risk, or...

Military conflict in the Middle East has led to the closure of the Strait of Hormuz, disrupting a key global energy and shipping route. This chokepoint closure is creating volatility across mining and metals companies, including Southern Copper (NYSE:SCCO), as fuel supply and transport risks rise. Investors are watching how higher energy costs and logistical challenges could affect operating expenses and margins for producers such as Southern Copper. Southern Copper, listed as NYSE:SCCO, is...